ACC 2024 | ORBITA-COSMIC

Coronary sinus reduction (CSR) is a relevant area of study for the treatment of refractory angina, with hopes of improving myocardial perfusion. However, to date, there are no conclusive data.

ACC 2024

The ORBITA-COSMIC study is a randomized, double-blind, placebo-controlled trial conducted at six centers in the UK. Researchers recruited patients with angina and chronic ischemia who were neither receiving optimal medical treatment nor scheduled for additional interventions (such as percutaneous coronary intervention or revascularization surgery). Each patient underwent stress cardiac MRI, and their angina was assessed using an application.

After sedation, patients were randomized 1:1 to undergo CSR or placebo. CSR involves percutaneous placement of a sand-clock-shaped stent (Neovasc Reducer) in the coronary sinus.

Primary endpoints evaluated were myocardial blood flow (MBF) imaging and angina symptoms measured using the ORBITA-app. Secondary outcomes included epicardial perfusion gradient, MBF at rest, myocardial perfusion reserve, and scar burden.

Read also: ACC 2024 | IVUS-DCB.

A total of 51 patients were included (25 in the CSR group and 26 in the placebo group), with a mean follow-up of 184 days. Most subjects were men (86%), and the average age was 67 years, with a high proportion of patients with a history of prior coronary bypass surgery.

Regarding MBF, there was no benefit compared with placebo when analyzing ischemic segments (0.06 mL/min per g [95% CrI –0.09 to 0.20]; Pr(benefit)=78.8%). However, CSR improved the endocardial-to-epicardial flow ratio (0.09 [95% CrI 0.00 to 0.17]; Pr(benefit)=98.2%). Regarding symptoms, at 6 months of follow-up, the CSR group showed a lower number of recorded angina episodes (odds ratio [OR], 1.40 [95% CrI 1.08 to 1.83]; Pr(Benefit)=99.4%).

The authors concluded that, while the hypothetical goal of improving MBF imaging was not achieved, patients treated with CSR showed better distribution of perfusion toward the endocardium, resulting in a lower incidence of angina episodes. This suggests that CSR could be considered as a therapeutic option for refractory angina.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: Reducción del seno coronario para el tratamiento de angina refractaria. 

Reference: Presentado por Dra. Rasha K Al-Lamee en ACC.24 Late-Breaking Clinical Trials, 6-8 de abril, Atlanta.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TAVR and Surgical Bailout: Temporal Trends and Clinical Implications

The evolution of transcatheter aortic valve replacement (TAVR), both regarding its planning and execution, has resulted in minimally invasive interventions with high safety levels....

Edge-to-Edge Repair in Atrial Secondary Tricuspid Regurgitation

Tricuspid regurgitation (TR) has been associated with higher morbimortality and a negative impact on quality of life.  In most cases, its main cause is a...

Percutaneous Treatment of Tricuspid Regurgitation with K-CLIP

Roughly 4% of the adult population presents tricuspid regurgitation (TR), a condition that might progress to severe or worse end-organ function, associated to hospitalizations...

PULSE Registry Subanalysis: Radial vs. Femoral Secondary Access

In view of its lower complications rate, the transfemoral approach is the most used in transcatheter aortic valve replacement (TAVR), vs. alternative access sites....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

RODIN-CUT: Successive Cutting Balloon Technique in Calcified Lesions

Moderate or severe coronary calcification can be a marker of poor prognosis in coronary artery disease, as it significantly increases the risk of failure...

Acute Coronary Syndrome with Multivessel Disease: Best Revascularization Strategy

The gold standard treatment for acute coronary syndrome (ACS), especially acute myocardial infarction (AMI) is primary angioplasty (PCI). However, 40 to 70% of ACS...

Improved Ejection Fraction in Chronic Total Occlusion?

Chronic total occlusions (CTO) represent a significant challenge in the current clinical practice, seeing as CTO percutaneous coronary intervention (PCI) is complex and involves...